Loading
A phase 3 trial of Favezelimab run by Merck Sharp & Dohme LLC, now recruiting.
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) is a phase 3 interventional study registered as NCT03486873 by Merck Sharp & Dohme LLC, with 3500 participants planned, started 2018-08-21. Conditions listed: Solid Tumors, Hematologic Malignancies. No results are recorded here; the registry entry is the source.
Shares Favezelimab, Merck & Co. (MSD), Immune checkpoint inhibitors.
Shares Favezelimab, Merck & Co. (MSD), Immune checkpoint inhibitors.
Shares Favezelimab, Merck & Co. (MSD), Immune checkpoint inhibitors.
Shares Favezelimab, Merck & Co. (MSD).
Shares Favezelimab, Merck & Co. (MSD).
Shares LAG-3 blockade, Favezelimab, Immune checkpoint inhibitors.